Mostra i principali dati dell'item
To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator
dc.contributor.author | Sorriento, Daniela | |
dc.contributor.author | Illario, Maddalena | |
dc.contributor.author | Finelli, Rosa | |
dc.contributor.author | Iaccarino, Guido | |
dc.date.accessioned | 2013-05-29T09:58:33Z | |
dc.date.available | 2013-05-29T09:58:33Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Sorriento D, Illario M, Finelli R, Iaccarino G. To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator. Translational Medicine @ UniSa 2012;4(9):73-85 | en_US |
dc.identifier.issn | 2239-9747 | en_US |
dc.identifier.uri | http://hdl.handle.net/10556/639 | |
dc.description.abstract | Nuclear factor B (NFB) is a transcription factor that plays an important role in carcinogenesis as well as in the regulation of inflammatory response. NFB is constitutively expressed in tumours where it induces the expression of genes which promote cell proliferation, apoptotic events, angiogenesis, invasion and metastasis. Furthermore, many cancer cells show aberrant or constitutive NFB activation that mediates resistance to chemo- and radio-therapy. Therefore, the inhibition of NFB activity appears a potential therapeutic strategy for cancer treatment. In this review, we focus on the role of NFB in carcinogenesis and summarize actual inhibitors of NFB that could be potential therapeutic target in cancer therapy. | en_US |
dc.format.extent | P. 73-85 | en_US |
dc.language.iso | en | en_US |
dc.source | UniSa. Sistema Bibliotecario di Ateneo | en_US |
dc.subject | Transcription factors | en_US |
dc.subject | IkB | en_US |
dc.subject | GRK5 | en_US |
dc.subject | Cancer | en_US |
dc.title | To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator | en_US |
dc.type | Article | en_US |